Two familiar market traps are hiding in this otherwise useful announcement: mistaking a study candidate for a buy signal, and treating the word undervalued like it fell from a mountaintop. BetterInvesting has named Electromed Inc. as its “Stock to Study” and Five Below Inc. as its “Undervalued Stock” for the January-February 2027 issue of its magazine. That is worth noticing. It is not, despite the urge to make everything a trade, a permission slip to buy either name.
Labels Start the Homework, Not the Purchase Order
Electromed, trading as ELMD on Nasdaq, gets the more restrained designation. “Stock to Study” is exactly the right framing for a company an investor may want to put through a disciplined review: sales trajectory, earnings quality, debt, cash generation, competitive position, and whether the current price leaves room for disappointment. Nothing in the announcement supplies those figures, and that blank space matters. A serious investor does not fill it with optimism just because a committee spotted something interesting.
Five Below, listed as FIVE, carries the punchier “Undervalued Stock” label. That will grab more eyeballs, naturally. Retail names can look cheap for excellent reasons, lousy reasons, or reasons that disappear after one solid quarter. The central question is never merely whether a stock trades below somebody’s estimate of worth. The question is whether the estimate rests on earnings power that can actually hold up. Consumer spending, store productivity, merchandise margins, inventory discipline, and expansion costs all deserve a hard look before anyone gets cute with a valuation multiple.
The Useful Part Is the Process
BetterInvesting is a national 501(c)(3) nonprofit that says it has been teaching individual investors since 1951 and has helped more than 5 million people learn to improve their financial futures. Fine by me. The market has no shortage of hot takes; it could use more people who know how to read a balance sheet without turning it into a séance.
The organization points readers toward its stock-selection and analysis tools, including a limited trial version for non-members, and specifically urges investors to use its Stock Selection Guide before making a decision. That is the heart of this update. The committee is not trying to hand out a magic ticker list. It is putting two companies on the workbench and asking investors to make judgments from fundamental data. Frankly, that is a healthier habit than chasing whatever name is screaming across a feed at 9:37 in the morning.
“Undervalued” without a defined estimate, assumptions, and a review of the risks is a conversation starter, not a conclusion.
Credentials Help, but Numbers Still Have the Last Word
The Editorial Advisory and Securities Review Committee includes Dan Rutter, Daniel J. Boyle, Marisa Bradbury, Philip Keating, Walter J. Kirchberger, and Anne Nichols; each is identified as a CFA. That is a respectable lineup, and it suggests the selections were not pulled from a hat. Still, even a room full of smart credentialed people cannot repeal business cycles, execution mistakes, competitive pressure, or a market that decides to punish a perfectly decent company for a while.
Investors should also be alert to the timing. These selections are for the January-February 2027 issue, announced November 18, 2026. A lot can shift between an initial screen, a published write-up, and the moment a reader finally investigates the stock. Prices move. Estimates move. Facts move. Any valuation work has a shelf life, and the shelf is shorter than people like to admit.
What Deserves a Closer Look From Here
For ELMD, the sensible next step is to examine the business fundamentals that made it study-worthy, rather than inventing a thesis from the designation alone. For FIVE, investors need to see the valuation assumptions behind the committee’s view and test them against the realities of a value-oriented retail operation. Compare historical results with expectations, then ask where those expectations could break. That last part is where portfolios are saved.
BetterInvesting’s disclaimer is not legal wallpaper. It says plainly that these choices are informational and educational, not endorsements or recommendations to purchase, and that investors should conduct their own review. Good. The cleanest takeaway is modest: ELMD and FIVE have earned a place on a research list. Whether either earns a place in a portfolio is a separate, tougher question—and it should stay that way.